secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2022-10-26T23:59:59+00:00
Accession:  0001104659-22-111340
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio publishes 24-month BRAVO study showing 2.6% recurrence rate with OviTex in hernia repair
--------------------------------------------------------------------------------

- BRAVO study 24-month analysis published in Annals of Medicine and Surgery; 92 patients enrolled.
- OviTex 1S Permanent demonstrated a 2.6% hernia recurrence rate at 24 months via open, laparoscopic, or robotic techniques.
- Patient quality-of-life showed statistically significant improvement from baseline at 3, 12, and 24 months.
- Surgical site occurrences in 38% of patients; 78% were high-risk (obesity, smoking, COPD, diabetes, etc.).
- CEO states commitment to ongoing BRAVO II study evaluating OviTex in robot-assisted repairs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465922111340/0001104659-22-111340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465922111340/tm2228895d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-111340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer